A recent Acute Medicine digest,
as sent to subscribers

Study Type: Retrospective cohort study using target trial emulation (TriNetX multinational EHR database, 2023 data), with propensity score matching.

Key Question: Is GLP-1 RA use before general anaesthesia associated with higher rates of postoperative pulmonary or gastrointestinal adverse events?

Key Findings:

• 21,948 patients after matching. GLP-1 RA users had a lower risk of pulmonary adverse events within one month (HR 0.682, 95% CI 0.496–0.938), with lower postoperative respiratory failure, hospitalisation and ED revisits.
• GI adverse events were marginally higher in GLP-1 RA users (HR 1.034, 95% CI 1.003–1.067); the authors describe the signal as modest.
• The abstract does not specify drug type, indication, fasting status or how aspiration was defined.

Clinical Relevance: Offers observational reassurance on pulmonary risk for patients on GLP-1 RAs presenting for surgery, relevant to UK perioperative guidance, though it does not settle fasting or withholding strategies.

Limitations: Observational EHR data carry residual confounding and coding uncertainty; results are not directly informative on aspiration and are not UK-specific.

Study Type: Multicentre prospective observational cohort study (n=3017, 2-year follow-up).

Key Question: Is pet ownership, and changes in ownership status, associated with migraine symptoms, psychological comorbidity and medication use?

Key Findings:

• Continuous pet ownership was associated with fewer attacks, lower pain severity, reduced medication use, less anxiety and sleep disturbance, and better migraine-specific quality of life (all P<0.001). Effect sizes are not reported in the abstract.
• Dog ownership showed more favourable profiles than cat or other pets (P<0.05).
• Acquiring a pet was associated with within-subject improvement; stopping was associated with loss of most benefit. More daily interaction time showed a graded association with improvement.

Clinical Relevance: Hypothesis-generating only; it offers no basis to recommend pet ownership in UK migraine pathways, though it highlights psychosocial and sleep factors worth addressing.

Limitations: Observational design leaves confounding and reverse causation (healthier patients keeping pets) unresolved, and the abstract does not state the population, setting or effect sizes.

Study Type: Small single-centre retrospective chart review with an uncontrolled empirical treatment trial (case series).

Key Question: Can patients with unexplained chronic GI symptoms and low-normal to mid-normal faecal elastase-1 (200–800 mcg/g) still respond to pancreatic enzyme replacement therapy (PERT)?

Key Findings:

• Of 102 elastase-1 tests (VA Connecticut, 2025), 34 fell in the 200–800 mcg/g range; 10 had persistent undiagnosed symptoms despite extensive investigation and empirical treatments.
• All 10 were offered a two-week PERT trial; 5 (50%) reported clinically significant improvement and remain on long-term PERT.
• No objective outcome measures, validated symptom scores or adverse events are reported in the abstract.

Clinical Relevance: Hypothesis-generating only; it suggests a normal faecal elastase does not fully exclude benefit from PERT, but UK practice should not change on this evidence.

Limitations: No control group or blinding, tiny selected sample with subjective outcomes, so placebo effect, natural history and selection bias cannot be excluded.

Study Type: Randomised controlled trial (1:1, 70 trial-protocol manuscripts submitted to BMJ Open; assessors masked, authors unaware).

Key Question: Does giving authors a SPIRIT 2025-based manuscript template during revision improve completeness of reporting in randomised trial protocols?

Key Findings:

• Adjusted completeness score (0-10 scale) was 0.61 points higher with the template (95% CI 0.20 to 1.01); scores rose from 5.42 to 6.70 (intervention) versus 5.77 to 6.32 (control).
• Largest gains were in recruitment, data collection methods, and data access reporting.
• Median time to revision was similar (27.1 vs 29.9 days). Of 13-14 survey respondents, 62% found the template time-consuming; 77% found it easy to use.

Clinical Relevance: Better-reported protocols support critical appraisal and reduce selective reporting in the trials that inform NHS practice, though this study addresses publishing processes rather than patient care directly.

Limitations: The effect was modest (the intervention group still scored only 6.7/10), and the survey response rate was low (40%), limiting conclusions on author experience.

Study Type: Prospective, open-label, stepped wedge cluster randomised controlled trial (18 Dutch community hospitals; 2267 participants).

Key Question: Does adding acetic acid chromoendoscopy (AAC) to standard Barrett's oesophagus surveillance increase detection of dysplasia and oesophageal adenocarcinoma?

Key Findings:

• Overall neoplasia detection rate was unchanged: 7.4% with AAC vs 7.1% without (adjusted OR 0.97, 95% CI 0.65 to 1.44).
• AAC more than doubled suspected lesions identified (14.0% vs 6.4%, P<0.001), but this did not translate into more neoplasia on targeted biopsy (2.1% vs 1.8%; OR 1.05, 95% CI 0.49 to 2.24).
• AAC was applied in 82% of participants allocated to it.

Clinical Relevance: In routine community practice, AAC adds no detection benefit over standard surveillance with random biopsies, so UK units need not adopt it, and it may increase unnecessary targeted biopsies.

Limitations: Open-label design with unequal allocation (63% control vs 37% intervention) and 18% non-adherence in the AAC arm may have diluted any true effect.

Study Type: Cannot be determined. The abstract field is empty. The title and journal suggest a commentary or narrative review, but this is inferred, not confirmed.

Key Question: Based on the title alone, the article appears to address whether statistically significant but small effect sizes, particularly in large computerised datasets, give a false sense of certainty. The actual question cannot be confirmed.

Key Findings: None can be reported. No abstract text, data, or conclusions were provided, and I cannot reliably infer findings from the title.

Clinical Relevance: If the title reflects the content, the article may be relevant to interpreting small-effect findings from large trials, registries, and EHR-based analyses used in NHS guideline development. This should be verified against the full text.

Limitations: No abstract was supplied, so no assessment of methods, scope, or conclusions is possible. Please provide the full text or abstract for a proper summary.

Study Type: Single-cohort retrospective observational study (n=790).

Key Question: Does estimated plasma volume status (ePVS), calculated from admission haemoglobin and haematocrit, predict 30-day mortality and blood product requirements in trauma patients?

Key Findings:

• 30-day mortality was 2.8% (22/790). Median ePVS was higher in non-survivors (5.76 vs 4.41, p<0.001).
• ePVS was independently associated with mortality after adjustment (OR 1.23, 95% CI 1.016–1.478); AUROC 0.776 (95% CI 0.666–0.887).
• ePVS correlated positively with RBC and FFP units transfused in the ED, within 24 hours, and over the whole admission.

Clinical Relevance: ePVS is a free, immediately available calculation that might support early risk stratification in major trauma, though it is not ready to inform transfusion or triage decisions in UK practice.

Limitations: The cohort was predominantly low-severity (median ISS 7.5) with few deaths, limiting power and generalisability to major trauma, and the retrospective single-cohort design lacks external validation.

Study Type: Multicentre, triple-blind RCT (3 university hospital EDs, Iran; n=73).

Key Question: Is IV ibuprofen 800 mg more effective or safer than IV ketorolac 30 mg for acute low back pain in the ED?

Key Findings:

• Mean VAS (0-100) was lower with ibuprofen at 10 min (49.6 vs 57.4; p=0.013) and 30 min (32.2 vs 40.7; p=0.038).
• At 30 min, 70.6% of ibuprofen patients reported mild pain versus 35.9% with ketorolac (p<0.001).
• ED length of stay was shorter with ibuprofen (magnitude not stated in abstract); rescue analgesia and adverse events were comparable.

Clinical Relevance: IV ibuprofen is a possible NSAID alternative to ketorolac for acute LBP, but the evidence is too limited to alter UK practice, where IV ibuprofen is rarely used for this indication and oral NSAIDs with cautious opioid use remain standard.

Limitations: Small sample (n=73) with unequal groups, a single short-term outcome window (30 min), no sample size calculation reported, and the 800 mg IV ibuprofen dose is higher than typical UK licensed dosing.